#1418 Phase II dose-selection, randomised, controlled trial of ASi BI 690517 with and without EMPA in CKD: subgroup analysis by T2D status
Dick de Zeeuw(University Medical Center Groningen), Hiddo J.L. Heerspink(University Medical Center Groningen), Zhichao Sun(Boehringer Ingelheim (Japan)), Shimoli Shah(Boehringer Ingelheim (Germany)), Juliane Meyerhoff(Boehringer Ingelheim (Germany)), Peter Rossing(Steno Diabetes Centers), Lisa Cronin(Boehringer Ingelheim (Germany)), Sibylle J. Hauske(Heidelberg University)
Cited by 1
Related Papers
K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification
|Data Archiving and Networked Services (DANS)|2002|11.7k
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
|New England Journal of Medicine|2017|7.7k
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k
Dapagliflozin in Patients with Chronic Kidney Disease
|New England Journal of Medicine|2020|5.2k